Search - tctmd.com

Displaying 121 - 140 of 174

Sort: Relevancy | Date

News Conference News SCAI 2019

Antithrombotic Use, Risk Perception, Varies Widely for PCI Patients With A-fib

Yael L. Maxwell

May 24, 2019

News Daily News

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Yael L. Maxwell

May 15, 2019

News Daily News

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Yael L. Maxwell

April 22, 2019

News Daily News

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Yael L. Maxwell

April 18, 2019

News Daily News

Initiative Helps Low-Resource Chinese Hospitals Provide Better ACS Care

L.A. McKeown

April 17, 2019

News Conference News ACC 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Yael L. Maxwell

March 22, 2019

News Daily News

Abnormal Coronary Reactivity in Women Portends Added CV, Death Risk in the Next Decade

Caitlin E. Cox

February 13, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

Shelley Wood

November 30, 2018

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Todd Neale

November 10, 2018

News Daily News

Final Phase III Bempedoic Acid Trial Proves Positive for LDL-Lowering

Shelley Wood

October 29, 2018

News Daily News

Vulnerable Plaque Components Seen on IVUS Not Linked With MACE, Two New Studies Show

Michael O'Riordan

October 17, 2018

News Daily News

Silent Infarcts Have Similar Mortality Over 10 Years as Clinically Recognized MI

Yael L. Maxwell

October 10, 2018

News Daily News

Varenicline Boosts Long-term Quit Rate in Post-ACS Smokers: EVITA

Caitlin E. Cox

March 26, 2018

News Conference News ACC 2018

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

Michael O'Riordan

March 14, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

News Daily News

Acute MI Quality Improvement Program Fails in India, but Researchers See Bright Side

L.A. McKeown

February 15, 2018

News Daily News

Routine Coronary CTA to Rule Out ACS in Acute Chest Pain Questioned in ROMICAT-II Subanalysis

L.A. McKeown

November 21, 2017

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

Advertisement

Antithrombotic Use, Risk Perception, Varies Widely for PCI Patients With A-fib

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Initiative Helps Low-Resource Chinese Hospitals Provide Better ACS Care

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Abnormal Coronary Reactivity in Women Portends Added CV, Death Risk in the Next Decade

TCTMD’s Top 10 Most Popular Stories for November 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Final Phase III Bempedoic Acid Trial Proves Positive for LDL-Lowering

Vulnerable Plaque Components Seen on IVUS Not Linked With MACE, Two New Studies Show

Silent Infarcts Have Similar Mortality Over 10 Years as Clinically Recognized MI

Varenicline Boosts Long-term Quit Rate in Post-ACS Smokers: EVITA

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Acute MI Quality Improvement Program Fails in India, but Researchers See Bright Side

Routine Coronary CTA to Rule Out ACS in Acute Chest Pain Questioned in ROMICAT-II Subanalysis

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content